hypertensive disease (syndrome of hyperactivity of liver Yang)
Conditions
Interventions
Case series : Polygonum cuspidatum leaf capsule
Sponsors
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) In accordance with hypertension disease diagnostic criteria, Grade I hypertension patients; (2) syndrome of hyperactivity of liver yang for TCM; (3) TCM syndrome score >=4; (4) age: 18~45 years old; (5) Some-one not taking antihypertensive drugs in the past, or who have to consume a kind of the antihypertensive drugs of western-medicine for at least 14 days (only calcium antagonists, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists) but not yet get to the standard in blood pressure; (6) signed Informed Consent Form voluntarily.
Exclusion criteria
Exclusion criteria: (1) hypertension combined with the following lesions:with cerebral vascular accident for 6 months , myocardial infarction or heart failure; the history of large arteries Aneurysm or dissecting aneurysm; definite angina; malignant or potential malignant arrhythmia; (2) patients with secondary hypertension; 2, grade 3 hypertension; (3) Agents other than antihypertensive agents who previously taken in addition to calcium antagonists, angiotensin converting enzyme inhibitor, angiotensin II receptor antagonist (4) with 2 or more drugs are used at the same time,; (5) TCM syndrome score less than 4; (6) aged under 18 or over 65 years; (7) pregnant or lactating women, women who cannot guarantee contraception during the trial; (8) allergic constitution or allergic to a variety of drugs; (9) autoimmune diseases or any serious fatal disease; (10) mental illness, outof the self-control, can not be expressed exactly; (11) liver and kidney function damaged: AST or / and ALT are 2 times more than the upper limit of the normal value in 1.2 times and above; (12) severe cardiopulmonary dysfunction; (13) diabetes blood glucose controlling is not good, the level of the fasting blood glucose>11mmol/L, or a combination of symptoms (such as diabetic nephropathy, peripheral neuropathy, etc.); (14) who has been in other clinical trials before this trial in a month; (15) the clinician considers that the patient who should not be present in the trial; (16) Patients has been into the group of this study in the past.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure measurement;24-hour ambulatory blood pressure;Hyperactivity of liver Yang Syndrome curative effect; | — |
Countries
China
Contacts
Public ContactRong Li
Outcome results
None listed